Is Corcept Therapeutics the Next Pharmaceutical Breakthrough? 

Photo of author
Written By Joel Gbolade

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a commercial-stage biopharmaceutical company headquartered in Menlo Park, CA, just outside of San Francisco. 

The company Specializes in the development of drugs for severe metabolic, oncologic, endocrine, and neurological disorders, and boasts a market capitalization of approximately $2.5 billion.

Its flagship product, Korlym (mifepristone) tablets, targets hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance.

Pipeline Potential

Corcept’s innovative approach revolves around modulating cortisol and its activity at the glucocorticoid receptor, offering promising treatments for various serious disorders, including Cushing’s Syndrome and cancers such as pancreatic, prostate, ovarian, triple-negative breast, and lung. 

Credits: DepositPhotos

The company’s Phase 3 trials (GRACE, GRADIENT) evaluating relacorilant, a compound for treating Cushing’s Syndrome, are anticipated to yield results in the second quarter of the fiscal year, with an NDA submission expected during the same period.

Read More: Walmart’s Acquisition of VIZIO Marks New Era for the Retail and Entertainment Industry

Financial Performance

Corcept Therapeutics recently reported its fourth-quarter results, exceeding expectations with GAAP earnings of 28 cents per share and a net income of $31.4 million.

Despite a challenging landscape, the company witnessed a notable year-over-year revenue increase of over 31%, amounting to $135.4 million for the quarter.

Encouragingly, management reaffirmed its revenue guidance for FY2024, projecting between $600 million to $640 million.

Analyst Insights & Market Sentiment

Analysts, including Truist Financial, Piper Sandler, and H.C. Wainwright, have reiterated Buy ratings on Corcept’s stock, underlining its growth potential.

However, short interest stands at nearly 23% of the outstanding float, with consistent insider selling observed throughout 2023. 

Nonetheless, with no long-term debt and a healthy balance sheet boasting over $425 million in cash and marketable securities, Corcept appears well-positioned for future growth.

Also Read: European Leaders Call for Urgent Support for Ukraine Amid Russian Advances

Strategic Outlook

Corcept’s profit surged to 94 cents a share in FY2023, driven by a 20% increase in sales to $482.4 million.

Looking ahead, analysts forecast a substantial rise in profits to $1.63 per share in FY2024, aligning with the company’s robust growth trajectory. 

With a forward earnings multiple of approximately 14 and forward sales multiple of 4, Corcept presents an attractive investment opportunity, particularly considering its substantial net cash reserves exceeding $400 million.

Risk Mitigation & Strategy

While challenges such as patent litigation issues persist, Corcept’s pipeline, notably relacorilant, offers promising prospects for addressing unmet medical needs.

Credits: DepositPhotos

The company’s strategic approach, including covered call orders to mitigate downside risks, underscores its commitment to delivering value to investors.

As developments unfold, monitoring Corcept’s progress in both litigation and drug development remains crucial for informed investment decisions.

Future Prospects

Corcept Therapeutics exhibits a compelling growth story supported by its robust product pipeline and solid financial footing.

While navigating challenges inherent in the biopharmaceutical industry, the company’s innovative solutions and strategic initiatives position it for sustained success. 

As investors assess the risk/reward profile, Corcept presents an enticing opportunity for long-term growth, with its transformative therapies poised to make a meaningful impact on patient care and shareholder value.

Read Next: Is This Energy Company Undervalued at the Current Price?


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.